Editorial policy
Every page on glp1doses.com follows the same rules. They are written down here so you can hold us to them.
Which source comes first
When sources disagree, we go with the one highest on this list:
- The FDA prescribing information (the label) on DailyMed.
- CMS, FDA and Federal Register publications.
- Peer-reviewed clinical trials.
- Manufacturer pages, used only for their own programs and prices.
- News reporting.
We cite telehealth providers only for their own prices and program terms, never for clinical claims. We do not cite other affiliate or review sites.
Every number is sourced
A number goes on this site only after we have read it at its primary source, meaning the original label, program or price page. Each number links to that source. When we quote the label, we quote it word for word.
How pages are checked
The glp1doses editorial team compares every page that touches dosing, safety, side effects, insurance criteria or prices with its primary sources before it publishes. Our build system also stops a page from publishing if a price or percentage on it can’t be traced to a source the page cites.
What we refuse to publish
- Any claim that a compounded product is the same as, identical to, or a generic of an FDA-approved medicine.
- Individual dose recommendations.
- Content about research-use-only peptides or reconstitution.
- Pages written to rank for a search term without adding sourced data or a real explanation.
Drafting and AI
We use software, including AI tools, to draft pages, run calculations and check the site. Every number is traced to a primary source before a page publishes.
Independence
Affiliate partners never see drafts. Provider rankings follow a published method based on cost alone, and how much a provider pays us is not part of it. We have no sponsorship, ownership or financial relationship with any drug manufacturer.
Corrections
If we get something wrong, we fix it. The corrections page explains how to report an error.